Skip to main content
Back to Journal Club

PAI-1 Inhibitor (TM5614) + Nivolumab for Anti-PD1 Refractory Melanoma - Phase II

Fujimura T, Yoshino K, Kato H, et al.
Dermatologic Surgery (2024)

JC: December 2024

This phase II trial evaluated the combination of a PAI-1 inhibitor (TM5614) with nivolumab in patients with anti-PD1 refractory melanoma. The study explored whether PAI-1 inhibition could overcome immune checkpoint therapy resistance, with preliminary results showing potential benefit in a subset of patients.

Take-Home Messages

  • •PAI-1 inhibition combined with nivolumab shows preliminary evidence of activity in anti-PD1 refractory melanoma.
  • •Novel combination strategies targeting the tumor microenvironment may help overcome immunotherapy resistance in advanced melanoma.

Topic

Melanoma

Melanoma margins, SLNB, staging, Mohs for melanoma in situ

Related MohsPedia Articles

Tumor Melanoma

Abstract

Anti-programmed cell death 1 antibodies (PD-1 Abs) are widely used for advanced melanoma, but information on the efficacy of anti-PD-1 Abs is limited in the Asian population. There remains an unmet need to improve the therapeutic effects of anti-PD-1 Ab-treatment, particularly in patients with melanoma who are refractory to anti-PD-1 Abs. The aim of this study was to evaluate anti-PD-1 Ab-treatment in combination with TM5614 (a plasminogen activator inhibitor-1 inhibitor) in patients with unr...

Literature review only. This summary is an editorial interpretation and may not reflect the complete findings of the original publication. Always refer to the full-text article for clinical decision-making.